GlassScriptPhysician profile
Justin Sigmon
NPI 1386885341
$2,470.40
in general payments reported to CMS, 2019-2025
26 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $128 · 2021: $106 · 2022: $420 · 2023: $312 · 2024: $277 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.36 |
| Education | $153.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $456.86 | 2019-2025 | Tremfya |
| Abbvie INC. | $391.40 | 2019-2025 | Rinvoq |
| Sun Pharmaceutical Industries INC. | $201.69 | 2019-2025 | |
| Genzyme Corporation | $190.79 | 2019-2025 | |
| Incyte Corporation | $133.75 | 2022-2023 | Opzelura |
| Celgene Corporation | $130.01 | 2019 | |
| Ucb, INC. | $116.69 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $106.05 | 2019-2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $93.62 | 2019-2024 | Jublia, Cabtreo |
| Amgen INC. | $87.29 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $79.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $65.61 | 2019-2025 | |
| Galderma Laboratories, L.P. | $53.47 | 2020-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $51.10 | 2019 | |
| Mayne Pharma Commercial LLC | $50.78 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $47.82 | 2025 | Vtama |
| Pfizer INC. | $38.88 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $35.75 | 2022-2023 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.11 | 2023 | Spevigo |
| Paratek Pharmaceuticals, INC. | $19.26 | 2023 | Nuzyra |
| Dusa Pharmaceuticals, INC. | $18.38 | 2019 | |
| Biofrontera INC. | $18.37 | 2019 | |
| Epi Health, LLC | $15.50 | 2020 | |
| Arcutis Biotherapeutics, INC. | $15.02 | 2023 | |
| Dermira, INC. | $14.44 | 2019 | |
| Almirall LLC | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Sigmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.